Stryker (SYK) - 14.00% Below 52-Week High: Buy or Wait?

Stock Details

Stryker Corporation (SYK), a prominent company in the healthcare sector within the medical devices industry, is based in United States and primarily trades on the NYQ.Currently, the stock is trading at $341.31. Over the past 52 weeks, it has ranged between $281.00 and $396.86. This places the current price at 86.0% of its 52-week high and 21.5% above its 52-week low. Recent trading volume was recorded at 551,332. The 14-day Relative Strength Index (RSI) stands at 58.97, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $321.85 by 6.05%. Similarly, it is above its 200-day moving average of $340.22 by 0.32%. The MACD histogram is 0.71, indicating bullish momentum (MACD Line: 6.61, Signal Line: 5.90). The International Securities Identification Number (ISIN) for this stock is US8636671013.

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

36.09

Above market average

Forward P/E

20.72

Earnings expected to grow

PEG Ratio

1.63

Reasonably valued

Price to Book

5.79

EV/EBITDA

19.68

EPS (TTM)

$9.62

Price to Sales

5.15

Beta

0.77

Less volatile than market

Q:How is SYK valued relative to its earnings and growth?

Stryker Corporation trades at a P/E ratio of 36.09, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 20.72 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 1.63 indicates reasonable value when growth is considered.

Q:What is SYK's risk profile compared to the market?

With a beta of 0.77, Stryker Corporation is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 5.79 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

14.43%

Operating Margin

27.02%

EBITDA

$7.38B

Return on Equity

16.51%

Return on Assets

8.16%

Revenue Growth (YoY)

9.40%

Earnings Growth (YoY)

44.10%

Q:How profitable and efficient is SYK's business model?

Stryker Corporation achieves a profit margin of 14.43%, meaning it retains $14.43 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 27.02% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 16.51% and ROA at 8.16%, the company generates strong returns on invested capital.

Q:What are SYK's recent growth trends?

Stryker Corporation's revenue grew by 9.40% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 44.10% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against Medical Devices industry averages for proper context.

Dividend Information

Dividend Per Share

$3.52

Dividend Yield

1.01%

Ex-Dividend Date

Sep 30, 2026

Dividend Date

Oct 30, 2026

Q:What dividend income can investors expect from SYK?

Stryker Corporation offers a dividend yield of 1.01%, paying $3.52 per share annually. This modest yield below 2% suggests the company prioritizes growth investments over current income. While the dividend provides some return, investors are likely attracted more by capital appreciation potential than income generation. To receive the next dividend, shares must be purchased before the ex-dividend date of Sep 30, 2026.

Q:How reliable is SYK's dividend for long-term investors?

The dividend sustainability can be assessed through the payout ratio - Stryker Corporation pays $3.52 per share in dividends against earnings of $9.62 per share, resulting in a payout ratio of 36.59%. This balanced payout between 30-60% suggests a sustainable dividend policy that allows both shareholder returns and business reinvestment. The dividend appears well-covered by earnings. The next dividend payment is scheduled for Oct 30, 2026.

Company Size & Market

Market Cap

$133.2B

Revenue (TTM)

$25.84B

Revenue/Share (TTM)

$67.50

Shares Outstanding

383.57M

Book Value/Share

$59.94

Asset Type

EQUITY

Q:What is SYK's market capitalization and position?

Stryker Corporation has a market capitalization of $133.2B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 383.57M shares outstanding, the company's ownership is relatively concentrated. As a major player in the Medical Devices industry, it competes with other firms in this sector.

Q:How does SYK's price compare to its book value?

Stryker Corporation's book value per share is $59.94, while the current stock price is $341.31, resulting in a price-to-book (P/B) ratio of 5.69. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$382.04

11.93% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for SYK?

27 analysts cover SYK with 78% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $382.04 implies 11.9% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on SYK?

Current analyst recommendations:7 Strong Buy, 14 Buy, 6 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 13, 2026, 02:07 AM

Technical Indicators

RSI (14-day)

58.97

Neutral

50-Day Moving Average

$321.85

6.05% above MA-50

200-Day Moving Average

$340.22

0.32% above MA-200

MACD Line

6.61

MACD Signal

5.90

MACD Histogram

0.71

Bullish

Q:What does SYK's RSI value tell investors?

The RSI (Relative Strength Index) for SYK is currently 58.97, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this confirms bullish conditions.

Q:How should traders interpret SYK's MACD and moving average crossovers?

MACD analysis shows the MACD line at 6.61 above the signal line at 5.90, with histogram at 0.71. This bullish crossover suggests upward momentum is building. The 50-day MA ($321.85) is below the 200-day MA ($340.22), forming a death cross pattern that often warns of extended weakness. Price is currently above both MAs, confirming strength.

Indicators last updated: Aug 13, 2026, 09:46 AM

Stryker Corporation (SYK) Stock